WirthLJ, ShermanE, RobinsonB, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med, 2020; 383(9):825–835.
2.
SubbiahV, HuMI, WirthLJ, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): A multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol, 2021; 9(8):491–501.
3.
JozaghiY, ZafereoM, WilliamsMD, et al. Neoadjuvant selpercatinib for advanced medullary thyroid cancer. Head Neck, 2021; 43(1):E7–E12.
4.
KaliszewskiK, LudwigM, LudwigB, et al.Update on the diagnosis and management of medullary thyroid cancer: What has changed in recent years?. Cancers (Basel), 2022; 14(15):3643.
5.
OwTJ, MehtaV, KimS, et al. Evaluation of survival and postoperative radiation among patients with advanced medullary thyroid carcinoma: An analysis of the National Cancer Database. Ann Surg Oncol, 2022; 29(4):2582–2591.
6.
AminMB, EdgeSB, GreeneFL, et al., (eds). American Joint Committee on Cancer Cancer Staging Manual, Eight Edition. Springer Nature, Springer International Publishing: Chicago; 2017.
7.
EisenhauerEA, TherasseP, BogaertsJ, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer, 2009; 45(2):228–247.
8.
U.S. Department of Health and HumanServices. Common Terminology Criteria for AdverseEvents, Version 5.0. 2017. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf [Last accessed: October 18, 2022].
9.
WangJR, ZafereoME, DaduR, et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF(V600E)-mutated anaplastic thyroid carcinoma. Thyroid, 2019; 29(8):1036–1043.
10.
U.S. National Library of Medicine. Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer, NCT04759911; 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT04759911 [Last accessed: October 18, 2022].
